The stock of InflaRx N.V. (NASDAQ:IFRX) is a huge mover today! The stock increased 2.76% or $0.085 during the last trading session, reaching $3.165. About 1.93 million shares traded or 62.43% up from the average. InflaRx N.V. (NASDAQ:IFRX) has risen 20.54% since June 12, 2018 and is uptrending. It has outperformed by 16.11% the S&P500.
The move comes after 9 months positive chart setup for the $82.18 million company. It was reported on Jun, 12 by Barchart.com. We have $3.35 PT which if reached, will make NASDAQ:IFRX worth $4.93M more.
Analysts await InflaRx N.V. (NASDAQ:IFRX) to report earnings on August, 8. They expect $-0.54 EPS, down 350.00 % or $0.42 from last year’s $-0.12 per share. After $-0.43 actual EPS reported by InflaRx N.V. for the previous quarter, Wall Street now forecasts 25.58 % negative EPS growth.
More notable recent InflaRx N.V. (NASDAQ:IFRX) news were published by: Globenewswire.com which released: “Richard Brudnick to Join InflaRx Board of Directors – GlobeNewswire” on February 14, 2019, also Nasdaq.com with their article: “Mid-Day Market Update: Crude Oil Down 4%; ReWalk Robotics Shares Spike Higher – Nasdaq” published on June 05, 2019, Schaeffersresearch.com published: “2 Stocks Heading for Their Best and Worst Days Ever – Schaeffers Research” on June 05, 2019. More interesting news about InflaRx N.V. (NASDAQ:IFRX) were released by: Nasdaq.com and their article: “Health Care Sector Update for 02/27/2019: GWPH,TNDM,SGYP – Nasdaq” published on February 27, 2019 as well as Globenewswire.com‘s news article titled: “InflaRx Announces Presentation of New Clinical Data with Lead Candidate IFX-1 in Hidradenitis Suppurativa – GlobeNewswire” with publication date: February 06, 2019.
InflaRx GmbH, a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology in the United States. The company has market cap of $82.18 million. The Company’s C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. It currently has negative earnings. The firm is involved developing IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and other chronic/autoimmune diseases, as well as IFX-2 for the treatment of chronic inflammation and autoimmune diseases.
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.